People - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

People on the move

PTSM: Pharmaceutical Technology Sourcing and Management
Volume 3, Issue 9

Corona, CA (Aug. 2)Watson Pharmaceuticals announced that Allen Chao, Ph.D., 61, its chairman, president and chief executive officer, will retire as president and chief executive officer, effective September 4, 2007. Chao will be succeeded by Paul M. Bisaro, 46, currently president and chief operating officer of Barr Pharmaceuticals (Woodcliff Lake, NJ), who has been named president and chief executive officer of Watson, effective September 4, 2007. Bruce L. Downey, Barr's chairman and chief executive officer, will assume these responsibilities on an interim basis.

Abbott Park, IL (Aug. 3)—Richard A. Gonzalez, president and chief operating officer, and a member of Abbott's board of directors, plans to retire after a 30-year career with the company. Gonzalez will remain with Abbott until Sept. 30, 2007.

Thousand Oaks, CA (Aug. 2)Amgen announced that Dennis Fenton, executive vice-president of operations, has elected to retire at the end of 2007 after 25 years with the company.

San Diego, CA (Aug. 2)— BioDuro, a life-sciences outsourcing company for the pharmaceutical and biotechnology industry with headquarters in San Diego, CA, and laboratory facilities in Beijing, China, appointed Steven M. Hutchins to the position of vice-president, business development and collaboration management.

Paris (Aug. 1)—David J. Williams relinquished his titles of president and chief executive officer of Sanofi Pasteur, the vaccines division of the Sanofi-Aventis Group . He will continue to serve as chairman of the board of Sanofi Pasteur until January 16, 2008, which will also mark his 30th anniversary with the company. His successor will be Wayne Pisano, formerly senior vice-president, global commercial operations and corporate strategy.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: PTSM: Pharmaceutical Technology Sourcing and Management,
Click here